Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Pfizer hired Marra all the way back in 2002, at which time the new Havas Health exec had spent a few years working at Merck ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

Bravo Store Systems, the leading point of sale provider for gun stores, pawnshops, and specialty retailers, announced today that it has been awarded the Fall 2024 Top Performer Award by SourceForge, ...

BioSpace, the leader in biopharma news and careers has published its 2025 Best Places to Work list. BioSpace's Best Places to ...

product launches and M&A transactions. Earlier in his career, he served as CFO at multiple publicly-traded biotech companies ...

These include the Coca-Cola Co. (KO) at $275 billion and Merck & Co. (MRK) at $260 billion ... They were the first cryptocurrency-related products offered by a regulated U.S. financial institution.

Over his 20-year tenure at Merck & Co., Inc., Eric helped to integrate research and commercial strategies in a number of key ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...